A Phase 1 interventional study of Fluticasone Propionate in Allergic Rhinitis, sponsored by GlaxoSmithKline. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2008-10-13.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. Fluticasone · Rhinitis, Allergic, Seasonal.
Among the 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal, this one is the 22nd largest by enrollment, is one of 7 that started in 2005, is one of 2 in phase 1, and was the 7th registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →None of the 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 7 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 326 across the 28 interventional studies. Of the 27 that completed or were terminated, 13 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 28 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
31 studies in Rhinitis, Allergic, Seasonal by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 31 finished, 10 (32%) have results posted.
Among the 31 studies in Rhinitis, Allergic, Seasonal by GlaxoSmithKline, this one is the 20th largest by enrollment of the 26 interventional ones that give a count, is one of 8 that started in 2005, is one of 4 in phase 1, and was the 8th registered.
GlaxoSmithKline’s Rhinitis, Allergic, Seasonal studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 31 in Rhinitis, Allergic, Seasonal:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is aimed at validating key therapeutic targets and biomarkers associated with allergic rhinitis. The therapeutic target expression will be investigated after a 7 day course of corticosteroid treatment followed by allergen challenge.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
This study's enrollment of 48 is below the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Browse Rhinitis, Allergic, Seasonal studies →GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
Compared within Rhinitis, Allergic, Seasonal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Rhinitis, Allergic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Change in expression of key allergy targets in the nose following exposure to allergen. Assessment of protein expression measured by western blotting and immunohistochemistry in nasal biopsy tissue.
Effect of corticosteroids treatment on the change in target expression following allergen challenge. Nasal lavage fluid and nasal secretions will be measured by ELISA and chemiluminescent assay.
This study is completed, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone
Rhinitis, Allergic, Seasonal →